title: Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland.
abstract: We present a review of 111 patients who were treated over an initial 3-year period with erlotinib. The median treatment time was 68 days and 59% of patients had stopped treatment within the first 3 months. However, 20 patients were on erlotinib for more than 12 months. Performance status and smoking history were the significant prognostic factors. The overall 3-year survival in patients who had never smoked was 26%.
authors.affiliation: Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK. ironside@blueyonder.co.uk
authors.forename: J A D
authors.initials: JA
authors.lastname: Ironside
authors.forename: J F
authors.initials: JF
authors.lastname: English
authors.forename: G R
authors.initials: GR
authors.lastname: Kerr
authors.forename: A
authors.initials: A
authors.lastname: Price
authors.forename: F A
authors.initials: FA
authors.lastname: Little
authors.forename: S C
authors.initials: SC
authors.lastname: Erridge
authors.forename: M J
authors.initials: MJ
authors.lastname: Mackean
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology; D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000188:drug therapy / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology; D018450:Disease Progression; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D012189:Retrospective Studies; D012606:Scotland; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride